[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:burkitt-lymphoma:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Burkitt Lymphoma","MS4A1 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[12],"Phase 2","RECRUITING","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[20],"Phase 1","2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07662928","Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:01.639696Z","2026-07-05T03:45:20.354557Z"]